Abstract
Interferon (IFN)-alpha, used for the treatment of chronic hepatitis C, has rarely been associated with the development of diabetes. Consensus interferon (CIFN), which is used for nonresponders, has not been associated with this complication. We describe the first case of new onset diabetes in a patient on CIFN. A 50-year-old man with chronic hepatitis C and no prior diabetes was started on IFN-alpha. After 24 weeks with a detectable viral load, he was switched to CIFN. Four weeks later, he presented in diabetic ketoacidosis which resolved with appropriate therapy without any ascertainable etiology (glutamic acid decarboxylase negative). Within 9 months he was off insulin, and is off all diabetic medications with an HgA1c of 5.6% 2 years after the episode.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
